HiFiBiO SAS to present advances in functional therapeutic antibody discovery at The European Antibody Congress on Tuesday, November 15, 2016.

PARIS & CAMBRIDGE, Mass.--()--HiFiBiO SAS today announced that the latest results from their CelliGOTM platform will be presented by Senior Scientist Dr. Annabelle Gerard as part of the 2016 European Antibody Conference. The presentations will feature the latest achievements in deep mining human and rodent immune repertoires for therapeutic antibody discovery and deep mining approaches to addressing challenging targets such as cell surface targets using in-droplet functional assays.

Presentation Title: Next-generation therapeutic antibodies by functional screening in droplets: Single-cell droplet based microfluidic technology. The presentation will be on Tuesday, Nov. 15 at 9:35 CET.

About HiFiBiO
HiFiBiO’s platform employs paired bar coding, next generation sequencing and rapid DNA synthesis coupled to high throughput cloning and expression enabling single cell-based screening of entire antibody-secreting B cell populations . Identification of diverse high quality leads is expected to lower the risk of developing optimized antibody drug candidates. The company has entered into multiple antibody discovery collaborations with leading pharmaceutical companies. Learn more at www.hifibio.com.

Contacts

HiFiBiO SAS
Colin J.H. Brenan, Ph.D., +1-781-248-9318
Chief Commercial Officer
c.brenan@hifibio.com

Release Summary

HiFiBiO SAS to present recent advances and results from its functional therapeutic antibody discovery platform - CelliGO(TM) - at the 2016 European Antibody Congress, Nov. 15th in Basel, Switzerland

Contacts

HiFiBiO SAS
Colin J.H. Brenan, Ph.D., +1-781-248-9318
Chief Commercial Officer
c.brenan@hifibio.com